Table 3.
Results for selected parameters in the plasma of HIV-infected men before (A) and after cART (B) and in the control group (C) with statistical analysis.
| Groups | A | B | C | p * | Post-Hoc |
|---|---|---|---|---|---|
| Me (IQR) |
Me (IQR) |
Me (IQR) | |||
|
IRS
[ng/mL] |
4.70 (1.60–21.80) |
8.90 (2.50–41.30) |
11.30 (3.20–38.30) |
0.02 | A:C = 0.02 B:C = 0.38 A:B = 0.13 |
|
MSTN
[ng/mL] |
162.80 (80.50–542.00) |
253.00 (105.20–2060.50) |
318.40 (129.40–1575.00) |
0.03 | A:C = 0.02 B:C = 0.23 A:B = 0.25 |
|
PYY
[pg/mL] |
156.30 (126.90–286.40) |
79.20 (31.40–262.60) |
181.50 (43.80–446.40) |
0.03 | A:C = 0.02 B:C = 0.30 A:B = 0.04 |
|
GLP-1
[ng/mL] |
209.60 (84.80–604.60) |
263.40 (132.00–2516.00) |
607.10 (184.60–1440.00) |
0.01 | A:C = 0.004 B:C = 0.24 A:B = 0.19 |
|
DPP-4
[ng/mL] |
239.80 (181.80–430.40) |
109.00 (51.30–1296.50) |
174.30 (66.70–1260.00) |
0.17 | A:C = 1.00 B:C = 0.45 A:B = 0.33 |
|
FETU-A
[ng/mL] |
265.2 (132.30–1387.00) |
363.90 (142.00–3568.50) |
620.60 (157.50–2302.00) |
0.12 | A:C = 0.10 B:C = 0.58 A:B = 0.58 |
|
PTX 3
[ng/mL] |
2.70 (1.10–7.90) |
2.60 (1.30–36.10) |
4.40 (1.50–17.40) |
0.03 | A:C = 0.04 B:C = 0.53 A:B = 0.13 |
|
SDF-1
[ng/mL] |
1.7 (0.70–6.40) |
1.70 (0.80–18.80) |
3.30 (1.10–8.50) |
0.19 | A:C = 0.10 B:C = 0.41 A:B = 1.0 |
|
RANTES
[ng/mL] |
330.50 (107.90–782.40) |
317.90 (165.90–3129.00) |
750.90 (182.60–2625.00) |
0.02 | A:C = 0.02 B:C = 0.42 A:B = 0.15 |
Abbreviations: IRS—irisin; MSTN—myostatin; PYY—peptide YY; GLP-1—glucagon-like peptide-1; DPP-4—dipeptidyl peptidase IV; FETU-A—fetuin A; PTX3—pentraxin 3; SDF-1-1—chemokine stromal cell-derived factor 1 regulated on activation; RANTES—normal T cell expressed and secreted; A—HIV-infected men before cART; B—HIV-infected men after cART; C—control group; Me—median; and IQR—interquartile range. * p—statistical significance by Kruskal–Wallis test.